{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:33:49Z","timestamp":1794641629445,"version":"4.9.1"},"reference-count":170,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Pharmacological antipsychotic drug interventions represent the cornerstone of the management of patients with schizophrenia and other psychotic spectrum disorders. The choice of the \u201cbest\u201d treatment should be made on the basis of several clinical domains. However, despite available treatments, the quality of life reported by patients with schizophrenia taking antipsychotics is still very poor, and this outcome is rarely taken into account in trials assessing the efficacy and effectiveness of antipsychotic treatments. Therefore, we performed a systematic review in order to assess the impact of antipsychotic treatment on patients\u2019 quality of life. In particular, we aimed to identify any differences in the improvement in quality of life according to the (a) type of formulation of antipsychotic drugs (i.e., oral vs. depot vs. long-acting injectable); (b) type of the drug (first vs. second vs. third generation); and (c) patients\u2019 clinical characteristics. One hundred and eleven papers were included in the review. The main findings were as follows: (1) quality of life is usually considered a secondary outcome in trials on the efficacy and effectiveness of drugs; (2) second-generation antipsychotics have a more positive effect on quality of life; and (3) long-acting injectable antipsychotics are associated with a more stable improvement in quality of life and with a good safety and tolerability profile. Our systematic review confirms that quality of life represents a central element for selecting the appropriate treatment for people with schizophrenia. In particular, the availability of new treatments with a better tolerability profile, a proven effectiveness on patients\u2019 cognitive and social functioning, and with a more stable blood concentration might represent the appropriate strategy for improving the quality of life of people with schizophrenia.<\/jats:p>","DOI":"10.3390\/brainsci13111577","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T05:04:56Z","timestamp":1699592696000},"page":"1577","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia"],"prefix":"10.3390","volume":"13","author":[{"given":"Gaia","family":"Sampogna","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Campania \u201cL. Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Di Vincenzo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Campania \u201cL. Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Giuliani","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Campania \u201cL. Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Menculini","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Perugia, 06132 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliana","family":"Mancuso","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Campania \u201cL. Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Arsenio","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Campania \u201cL. Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8995-9020","authenticated-orcid":false,"given":"Salvatore","family":"Cipolla","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Campania \u201cL. Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Della Rocca","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Campania \u201cL. Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3344-1000","authenticated-orcid":false,"given":"Vassilis","family":"Martiadis","sequence":"additional","affiliation":[{"name":"Department of Mental Health, ASL Napoli 1 Centro, 80147 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Salvina","family":"Signorelli","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Catania, 95124 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Fiorillo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Campania \u201cL. Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr. Bull."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/wps.20998","article-title":"Psychiatric diagnosis and treatment in the 21st century: Paradigm shifts versus incremental integration","volume":"21","author":"Stein","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: A systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/0972-6748.196045","article-title":"Prevalence of comorbid anxiety disorders in schizophrenia","volume":"25","author":"Kiran","year":"2016","journal-title":"Ind. Psychiatry J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"800047","DOI":"10.3389\/fpsyt.2021.800047","article-title":"Prevalence of Comorbid Personality Disorder in Psychotic and Non-psychotic Disorders","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5152\/npa.2015.8827","article-title":"Prevalence of Substance Use in Patients Diagnosed with Schizophrenia","volume":"53","year":"2016","journal-title":"Noro Psikiyatr. Ars."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/wps.20809","article-title":"The clinical characterization of the patient with primary psychosis aimed at personalization of management","volume":"20","author":"Maj","year":"2021","journal-title":"World Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/wps.20997","article-title":"The clinical characterization of the adult patient with bipolar disorder aimed at personalization of management","volume":"21","author":"McIntyre","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1192\/j.eurpsy.2022.2349","article-title":"The biopsychosocial model of schizophrenia and cancer: Unraveling the etiopathogenesis of complex diseases","volume":"65","author":"Fiorillo","year":"2022","journal-title":"Eur. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.12740\/PP\/132953","article-title":"Etiopathogenesis of schizophrenia\u2014The state of the art for 2021","volume":"55","author":"Rybakowski","year":"2021","journal-title":"Psychiatr Pol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/wps.20922","article-title":"Person-centred care planning as foundational to clinical practice","volume":"21","author":"Davidson","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"115495","DOI":"10.1016\/j.psychres.2023.115495","article-title":"Moderators of functional improvement after integrative cognitive remediation in schizophrenia: Toward a personalized treatment approach","volume":"329","author":"Sampedro","year":"2023","journal-title":"Psychiatry Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/wps.20912","article-title":"The importance of listening to patient preferences when making mental health care decisions","volume":"20","author":"Swift","year":"2021","journal-title":"World Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/wps.20986","article-title":"Subjectivity, psychosis and the science of psychiatry","volume":"21","author":"Sass","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Wong, D.F.K., Cheung, Y.C.H., Zhuang, X., Ng, Y.P., Oades, L.G., and Ye, S.S. (2023). Towards an integrative hope-dysfunctional beliefs perspective to personal recovery in schizophrenia: A path analysis. BMC Psychiatry, 23.","DOI":"10.1186\/s12888-023-05135-7"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/wps.21000","article-title":"Psychiatric diagnosis and treatment in the 21st century: Paradigm shifts or power shifts?","volume":"21","author":"Thornicroft","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/wps.21006","article-title":"Challenges and chances for mental health care in the 21st century","volume":"21","author":"Heinz","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/wps.20977","article-title":"Reappraising the variability of effects of antipsychotic medication in schizophrenia: A meta-analysis","volume":"21","author":"McCutcheon","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/wps.20972","article-title":"Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: A network meta-analysis of 92 randomized trials including 22,645 participants","volume":"21","author":"Ostuzzi","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00406-014-0528-2","article-title":"What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial","volume":"265","author":"Schennach","year":"2015","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/wps.20940","article-title":"Community-based social interventions for people with severe mental illness: A systematic review and narrative synthesis of recent evidence","volume":"21","author":"Killaspy","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/wps.20941","article-title":"The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: An umbrella review and meta-analytic evaluation of recent meta-analyses","volume":"21","author":"Leichsenring","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100285","DOI":"10.1016\/j.scog.2023.100285","article-title":"Feasibility of six-month outpatient cognitive remediation in schizophrenia: Experience from the randomized controlled integrated social cognition and social skills therapy study","volume":"33","author":"Schuster","year":"2023","journal-title":"Schizophr. Res. Cogn."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"112560","DOI":"10.1016\/j.psychres.2019.112560","article-title":"Predictive factors of functional remission in patients with early to mid-stage schizophrenia treated by long acting antipsychotics and the specific role of clinical remission","volume":"281","author":"Gorwood","year":"2019","journal-title":"Psychiatry Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/0004867419837358","article-title":"Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome","volume":"53","author":"Olagunju","year":"2019","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"204512531987003","DOI":"10.1177\/2045125319870033","article-title":"Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia","volume":"9","author":"Taylor","year":"2019","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/wps.20859","article-title":"Internalizing psychopathology and all-cause mortality: A comparison of transdiagnostic vs. diagnosis-based risk prediction","volume":"20","author":"Kim","year":"2021","journal-title":"World Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s11136-020-02470-0","article-title":"Quality of life in patients with severe mental illness: A cross-sectional survey in an integrated outpatient health care model","volume":"29","author":"Martin","year":"2020","journal-title":"Qual. Life Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/wps.21010","article-title":"Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: Results from a nationwide active comparator-controlled cohort study","volume":"21","author":"Andersen","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_30","first-page":"245103","article-title":"Health-Related Quality of Life and Overall Life Satisfaction in People with Serious Mental Illness","volume":"2012","author":"Barnes","year":"2012","journal-title":"Schizophr. Res. Treat."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.comppsych.2012.03.003","article-title":"Effects of antipsychotic medications on quality of life and psychosocial functioning in patients with early-stage schizophrenia: 1-year follow-up naturalistic study","volume":"53","author":"Guo","year":"2012","journal-title":"Compr. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: A large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/wps.20614","article-title":"The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: A meta-review of meta-analyses of randomized controlled trials","volume":"18","author":"Vancampfort","year":"2019","journal-title":"World Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1026409326690","article-title":"A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation","volume":"6","author":"Awad","year":"1997","journal-title":"Qual. Life Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00005053-199802000-00002","article-title":"Quality of life in schizophrenia: Insight and subjective response to neuroleptics","volume":"186","author":"Browne","year":"1998","journal-title":"J. Nerv. Ment. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/S0033291797005874","article-title":"Quality of life measurement in schizophrenia: Reconciling the quest for subjectivity with the question of reliability","volume":"28","author":"Voruganti","year":"1998","journal-title":"Psychol. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/PPA.S16800","article-title":"Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence","volume":"5","author":"Kelin","year":"2011","journal-title":"Patient Prefer. Adherence"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3109\/13651501.2011.554987","article-title":"Identifying an optimal treatment for schizophrenia: A 2-year randomized controlled trial comparing integrated care to a high-quality routine treatment","volume":"15","author":"Sungur","year":"2011","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Cortesi, P.A., Mencacci, C., Luigi, F., Pirfo, E., Berto, P., Sturkenboom, M.C., Lopes, F.L., Giustra, M.G., Mantovani, L.G., and Scalone, L. (2013). Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: Results from the COMETA study. BMC Psychiatry, 13.","DOI":"10.1186\/1471-244X-13-98"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.eurpsy.2015.11.007","article-title":"A cluster-analytical approach toward real-world outcome in outpatients with stable schizophrenia","volume":"32","author":"Rocca","year":"2016","journal-title":"Eur. Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.comppsych.2015.11.002","article-title":"Sexual dysfunction and its impact on quality of life in Chinese patients with schizophrenia treated in primary care","volume":"65","author":"Hou","year":"2016","journal-title":"Compr. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0020764015585330","article-title":"Quality of life and clinical characteristics in a nonselected sample of patients with schizophrenia","volume":"62","author":"Medici","year":"2016","journal-title":"Int. J. Soc. Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2147\/NDT.S122483","article-title":"Quality of life, self-stigma, and hope in schizophrenia spectrum disorders: A cross-sectional study","volume":"13","author":"Vrbova","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2147\/PPA.S265312","article-title":"Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia","volume":"14","author":"Fond","year":"2020","journal-title":"Patient Prefer. Adherence"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/0004867414536931","article-title":"Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: Findings of the third national survey on use of psychotropic medications in China","volume":"49","author":"Li","year":"2015","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5414\/CP202413","article-title":"Antipsychotic polypharmacy and quality of life in patients with schizophrenia treated in primary care in China","volume":"54","author":"Hou","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_47","first-page":"S348","article-title":"Efficacy of LAI in first episode psychosis: An observational study--clinical reports","volume":"27","author":"Cervone","year":"2015","journal-title":"Psychiatr. Danub."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hup.1143","article-title":"Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: Post hoc analysis from a 3-year observational study","volume":"25","author":"Araujo","year":"2010","journal-title":"Hum. Psychopharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/13651500903282881","article-title":"Cognitive function, social functioning and quality of life in first-episode psychosis: A 1-year longitudinal study","volume":"14","author":"Popolo","year":"2010","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hup.2469","article-title":"Rate and predictors of non-response to first-line antipsychotic treatment in first-episode schizophrenia","volume":"30","author":"Chiliza","year":"2015","journal-title":"Hum. Psychopharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/eip.12141","article-title":"Combining depot antipsychotic with an assertive monitoring programme for treating first-episode schizophrenia in a resource-constrained setting","volume":"10","author":"Chiliza","year":"2016","journal-title":"Early Interv. Psychiatry"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4103\/ijmr.IJMR_279_15","article-title":"Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study","volume":"144","author":"Sahni","year":"2016","journal-title":"Indian J. Med. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/eip.12246","article-title":"Quality of life and functioning in first-episode psychosis Chinese patients with different antipsychotic medications","volume":"10","author":"Lee","year":"2016","journal-title":"Early Interv. Psychiatry"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3389\/fpsyt.2019.00935","article-title":"Aripiprazole Long-Acting Injection During First Episode Schizophrenia-An Exploratory Analysis","volume":"10","author":"Giordano","year":"2020","journal-title":"Front. Psychiatry"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41537-019-0091-y","article-title":"Early recovery in the first 24 months of treatment in first-episode schizophrenia-spectrum disorders","volume":"6","author":"Phahladira","year":"2020","journal-title":"NPJ Schizophr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.4088\/JCP.09m05113yel","article-title":"Assertive community treatment as part of integrated care versus standard care: A 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial)","volume":"71","author":"Lambert","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/13651500903282873","article-title":"Perceptions on efficacy and side effects of conventional depot antipsychotics (CDA) and atypical depot antipsychotics (ADA): Psychiatrists versus patients in Hong Kong","volume":"14","author":"Tsang","year":"2010","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0269881109358198","article-title":"Costs and outcomes associated with an aripiprazole add-on or switching open-label study in psychosis","volume":"25","author":"Aitchison","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"ref_59","unstructured":"American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association. [3rd ed.]."},{"key":"ref_60","unstructured":"American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association. [4th ed.]."},{"key":"ref_61","unstructured":"American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association. [4th ed.]. text revision."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association. [5th ed.].","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref_63","unstructured":"World Health Organization (1977). International Statistical Classification of Diseases and Related Health Problems, World Health Organization. [9th ed.]."},{"key":"ref_64","unstructured":"World Health Organization (1990). International Statistical Classification of Diseases and Related Health Problems, World Health Organization. [10th ed.]."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology, U.S. Department of Health, Education, and Welfare.","DOI":"10.1037\/e591322011-001"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1744-859X-9-20","article-title":"Global Assessment of Functioning (GAF): Properties and frontier of current knowledge","volume":"9","author":"Aas","year":"2010","journal-title":"Ann. Gen. Psychiatry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophr. Bull."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Michalos, A.C. (2014). Encyclopedia of Quality of Life and Well-Being Research, Springer.","DOI":"10.1007\/978-94-007-0753-5"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity","volume":"34","author":"Ware","year":"1996","journal-title":"Med. Care"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med. Care"},{"key":"ref_73","first-page":"892","article-title":"Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients","volume":"41","author":"Meltzer","year":"1990","journal-title":"Hosp. Community Psychiatry"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e2777","DOI":"10.1002\/hup.2777","article-title":"Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post-hoc analysis of a long-term open-label study","volume":"36","author":"Ishigooka","year":"2021","journal-title":"Hum. Psychopharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.2147\/NDT.S320021","article-title":"Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study","volume":"17","author":"Iyo","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"McEvoy, J.P., Weiden, P.J., Lysaker, P.H., Sun, X., and O\u2019Sullivan, A.K. (2021). Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia. BMC Psychiatry, 21.","DOI":"10.1186\/s12888-021-03124-2"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Nasrallah, H.A., Weiden, P.J., Walling, D.P., Du, Y., Yao, B., Yagoda, S., and Claxton, A. (2021). Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: Exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study. BMC Psychiatry, 21.","DOI":"10.1186\/s12888-021-03420-x"},{"key":"ref_78","first-page":"829","article-title":"Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs","volume":"18","author":"Iorio","year":"2022","journal-title":"Dis. Treat."},{"key":"ref_79","first-page":"244","article-title":"Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group","volume":"22","author":"Awad","year":"1997","journal-title":"J. Psychiatry Neurosci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0893-133X(97)00111-5","article-title":"Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial","volume":"18","author":"Hamilton","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/JCP.0b013e3181f28dff","article-title":"A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia","volume":"30","author":"Lin","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/JCP.0b013e3181e69042","article-title":"A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: A 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial","volume":"30","author":"Stahl","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.comppsych.2010.05.008","article-title":"Subjective quality of life in patients with chronic schizophrenia: Relationships between psychosocial and clinical characteristics","volume":"52","author":"Kao","year":"2011","journal-title":"Compr. Psychiatry"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3906\/sag-1405-100","article-title":"Self-perception of quality of life in patients treated with antipsychotics","volume":"45","author":"Dima","year":"2015","journal-title":"Turk. J. Med. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S2215-0366(16)00085-7","article-title":"Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: A double-blind, randomised study","volume":"3","author":"Heinze","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.euroneuro.2019.03.014","article-title":"Disparate effects of first and second generation antipsychotics on cognition in schizophrenia\u2014Findings from the randomized NeSSy trial","volume":"29","author":"Scharpenberg","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0447.1996.tb10664.x","article-title":"Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics","volume":"93","author":"Larsen","year":"1996","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_88","unstructured":"Morss, S.E., Lenert, L.A., and Faustman, W.O. (November, January 30). The side effects of antipsychotic drugs and patients\u2019 quality of life: Patient education and preference assessment with computers and multimedia. Proceedings of the Annual Symposium on Computer Application in Medical Care, Washington, DC, USA."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0165-1781(97)00062-0","article-title":"Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine","volume":"72","author":"Galletly","year":"1997","journal-title":"Psychiatry Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.schres.2009.05.002","article-title":"Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study","volume":"113","author":"Sacchetti","year":"2009","journal-title":"Schizophr. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/0973-1229.90181","article-title":"Stigma of Mental Illness-1: Clinical reflections","volume":"10","author":"Shrivastava","year":"2012","journal-title":"Mens Sana Monogr."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11126-014-9290-x","article-title":"Quality of life in patients with schizophrenia: The impact of socio-economic factors and adverse effects of atypical antipsychotics drugs","volume":"85","author":"Ribeiro","year":"2014","journal-title":"Psychiatr. Q."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.comppsych.2013.11.002","article-title":"Association between subjective well-being and depressive symptoms in treatment-resistant schizophrenia before and after treatment with clozapine","volume":"55","author":"Kim","year":"2014","journal-title":"Compr. Psychiatry"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0035-1555939","article-title":"Clozapine prescription and quality of life in Chinese patients with schizophrenia treated in primary care","volume":"48","author":"Hou","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.schres.2015.07.048","article-title":"Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002\u20132012)","volume":"168","author":"Li","year":"2015","journal-title":"Schizophr. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.schres.2020.02.002","article-title":"Does clozapine improves cognition in patients with treatment resistant schizophrenia?: An exploratory study","volume":"218","author":"Verma","year":"2020","journal-title":"Schizophr. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/JCP.0b013e318248dfb8","article-title":"Augmenting clozapine with sertindole: A double-blind, randomized, placebo-controlled study","volume":"32","author":"Nielsen","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1744-859X-9-35","article-title":"A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting","volume":"9","author":"Hsieh","year":"2010","journal-title":"Ann. Gen. Psychiatry"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40263-012-0003-4","article-title":"Effect of aripiprazole on verbal memory and fluency in schizophrenic patients: Results from the ESCAPE study","volume":"26","author":"Bervoets","year":"2012","journal-title":"CNS Drugs"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1751-7893.2012.00379.x","article-title":"Effectiveness of aripiprazole in adolescents and young adults with schizophrenia spectrum disorders: Comparison of first-episode to recurrent psychosis","volume":"7","author":"Huang","year":"2013","journal-title":"Early Interv. Psychiatry"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.comppsych.2010.12.003","article-title":"Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia","volume":"53","author":"Osuntokun","year":"2012","journal-title":"Compr. Psychiatry"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eurpsy.2011.06.008","article-title":"A prospective, multicentre, open-label study to evaluate the effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia","volume":"27","author":"Peuskens","year":"2012","journal-title":"Eur. Psychiatry"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/08039488.2013.799228","article-title":"Neurocognitive effects of aripiprazole in adolescents and young adults with schizophrenia","volume":"68","author":"Yeh","year":"2014","journal-title":"Nord. J. Psychiatry"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1185\/03007995.2014.898630","article-title":"Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR)","volume":"30","author":"Schreiner","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.euroneuro.2014.03.001","article-title":"Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: Findings from the NIMH CATIE study","volume":"24","author":"Fervaha","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.schres.2017.01.004","article-title":"A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia","volume":"185","author":"Lin","year":"2017","journal-title":"Schizophr. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11126-012-9233-3","article-title":"Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia","volume":"84","author":"Chaves","year":"2013","journal-title":"Psychiatr. Q."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.schres.2015.08.015","article-title":"Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia","volume":"169","author":"Schreiner","year":"2015","journal-title":"Schizophr. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/YIC.0000000000000030","article-title":"A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea","volume":"29","author":"Lee","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/NMD.0000000000000069","article-title":"Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia","volume":"202","author":"Leatherman","year":"2014","journal-title":"J. Nerv. Ment. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMoa1005987","article-title":"Long-acting risperidone and oral antipsychotics in unstable schizophrenia","volume":"364","author":"Rosenheck","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_112","first-page":"27","article-title":"Schizophrenia Outpatient Health Outcomes study: Twelve-month findings","volume":"3","author":"Novick","year":"2012","journal-title":"Pragmat. Obs. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/JCP.0b013e3182114d21","article-title":"Differential 3-year effects of first- versus second-generation antipsychotics on subjective well-being in schizophrenia using marginal structural models","volume":"31","author":"Lambert","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1524-4733.2008.00495.x","article-title":"Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study","volume":"12","author":"Alonso","year":"2009","journal-title":"Value Health"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/NDT.S188337","article-title":"Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan","volume":"15","author":"Sugawara","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0924-9338(98)80141-7","article-title":"Quality of life in schizophrenia: Long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment","volume":"13","author":"Bobes","year":"1998","journal-title":"Eur. Psychiatry"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11126-015-9385-z","article-title":"Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users","volume":"87","author":"Ribeiro","year":"2016","journal-title":"Psychiatr. Q."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12991-014-0039-6","article-title":"Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response-a prospective open-label study","volume":"14","author":"Hashimoto","year":"2015","journal-title":"Ann. Gen. Psychiatry"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2147\/NDT.S73992","article-title":"Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine","volume":"11","author":"Montgomery","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Awad, G., Hassan, M., Loebel, A., Hsu, J., Pikalov, A., and Rajagopalan, K. (2014). Health-related quality of life among patients treated with lurasidone: Results from a switch trial in patients with schizophrenia. BMC Psychiatry, 14.","DOI":"10.1186\/1471-244X-14-53"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1185\/03007995.2013.869201","article-title":"Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: Core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: The RISPALI study","volume":"30","author":"Gattaz","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2190\/PM.45.2.c","article-title":"Switching to ziprasidone in the clinical practice setting: An open-label study","volume":"45","year":"2013","journal-title":"Int. J. Psychiatry Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.euroneuro.2013.07.006","article-title":"Subjective well-being in schizophrenia: A randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER)","volume":"23","author":"Naber","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/YIC.0b013e3283633a83","article-title":"Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: A randomized, double-blind study","volume":"28","author":"Lin","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.pnpbp.2011.11.004","article-title":"Effect of olanzapine orally disintegrating tablet versus oral standard tablet on body weight in patients with schizophrenia: A randomized open-label trial","volume":"36","author":"Kusumi","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/PPA.S26002","article-title":"Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan","volume":"5","author":"Ye","year":"2011","journal-title":"Patient Prefer. Adherence"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1440-1819.2012.02351.x","article-title":"Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan","volume":"66","author":"Ye","year":"2012","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_128","first-page":"596898","article-title":"Second generation antipsychotics improve sexual dysfunction in schizophrenia: A randomised controlled trial","volume":"2011","author":"Mahmoud","year":"2011","journal-title":"Schizophr. Res Treat."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.schres.2009.12.013","article-title":"Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia","volume":"118","author":"Kinon","year":"2010","journal-title":"Schizophr. Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/WNF.0b013e3181a5d08c","article-title":"Association of adverse drug effects with subjective well-being in patients with schizophrenia receiving stable doses of risperidone","volume":"32","author":"Kim","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Awad, G., Ng-Mak, D., Rajagopalan, K., Hsu, J., Pikalov, A., and Loebel, A. (2016). Long-term health-related quality of life improvements among patients treated with lurasidone: Results from the open-label extension of a switch trial in schizophrenia. BMC Psychiatry, 16.","DOI":"10.1186\/s12888-016-0879-5"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/ppc.12278","article-title":"Determinants of quality of life among people diagnosed with schizophrenia at outpatient clinics","volume":"55","author":"Hasan","year":"2019","journal-title":"Perspect. Psychiatr. Care"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/YIC.0000000000000092","article-title":"Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: A flexible-dose approach","volume":"30","author":"Mauri","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_134","first-page":"869","article-title":"Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People\u2019s Republic of China","volume":"10","author":"Ye","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00406-012-0316-9","article-title":"Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: Results of a prospective observational trial","volume":"262","author":"Kilian","year":"2012","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4088\/JCP.09m05459yel","article-title":"Relapse prevention in first-episode schizophrenia-maintenance vs intermittent drug treatment with prodrome-based early intervention: Results of a randomized controlled trial within the German Research Network on Schizophrenia","volume":"72","author":"Gaebel","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0929-6646(10)60066-6","article-title":"Symptomatic resolution among Chinese patients with schizophrenia and associated factors","volume":"109","author":"Li","year":"2010","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.psychres.2010.04.006","article-title":"Antipsychotic medication and social cue recognition in chronic schizophrenia","volume":"178","author":"Roberts","year":"2010","journal-title":"Psychiatry Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/2045125315596897","article-title":"Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: Which roe for long-acting risperidone?","volume":"5","author":"Niolu","year":"2015","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.schres.2015.07.007","article-title":"Qualify: A randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia","volume":"168","author":"Naber","year":"2015","journal-title":"Schizophr. Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3109\/13651501.2014.988268","article-title":"The effects of switching from oral to LAI antipsychotic treatment on subjective experience of schizophrenic and schizoaffective patients: Preliminary results","volume":"19","author":"Pietrini","year":"2015","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1017\/neu.2013.7","article-title":"Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)","volume":"25","author":"Rouillon","year":"2013","journal-title":"Acta Neuropsychiatr."},{"key":"ref_143","first-page":"1125","article-title":"Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection","volume":"10","author":"Novick","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Ascher-Svanum, H., Zhao, F., Detke, H.C., Nyhuis, A.W., Lawson, A.H., Stauffer, V.L., Montgomery, W., Witte, M.M., and McDonnell, D.P. (2011). Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia. BMC Psychiatry, 11.","DOI":"10.1186\/1471-244X-11-152"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-10-35","article-title":"Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: A time trade-off study","volume":"10","author":"Osborne","year":"2012","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Peuskens, J., Porsdal, V., Pecenak, J., Handest, P., D\u2019yachkova, Y., Brousil, R., and Deberdt, W. (2012). Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: A pooled analysis. BMC Psychiatry, 12.","DOI":"10.1186\/1471-244X-12-130"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1185\/03007995.2012.657300","article-title":"Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia","volume":"28","author":"Witte","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_148","first-page":"237","article-title":"The Effect of Switching to Long-Acting Injection (LAI) Antipsychotic Therapy on Patients with Schizophrenia","volume":"47","author":"Strunoiu","year":"2021","journal-title":"Curr. Health Sci. J."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/13651501.2021.1912358","article-title":"Self- and caregiver-perceived disability, subjective well-being, quality of life and psychopathology improvement in long-acting antipsychotic treatments: A 2-year follow-up study","volume":"25","author":"Pietrini","year":"2021","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eurpsy.2018.04.004","article-title":"Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study","volume":"52","author":"Llorca","year":"2018","journal-title":"Eur. Psychiatry"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.schres.2017.04.013","article-title":"Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study","volume":"192","author":"Naber","year":"2018","journal-title":"Schizophr. Res."},{"key":"ref_152","first-page":"40","article-title":"Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate","volume":"20","author":"Potkin","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/JCP.0000000000000993","article-title":"Comparison of Paliperidone Palmitate and Second-Generation Oral Antipsychotics in Terms of Medication Adherence, Side Effects, and Quality of Life","volume":"39","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-0029-1239592","article-title":"Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia?","volume":"43","author":"Schmauss","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.eurpsy.2009.09.001","article-title":"Establishing remission and good clinical functioning in schizophrenia: Predictors of best outcome with long-term risperidone long-acting injectable treatment","volume":"25","author":"Lambert","year":"2010","journal-title":"Eur. Psychiatry"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.eurpsy.2018.06.002","article-title":"Changes in attitude towards LAI antipsychotic maintenance treatment: A two-year follow-up study","volume":"53","author":"Pietrini","year":"2018","journal-title":"Eur. Psychiatry"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.schres.2016.03.020","article-title":"Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study","volume":"174","author":"Isitt","year":"2016","journal-title":"Schizophr. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1007\/s11136-019-02214-9","article-title":"A systematic review of quality of life research in medicine and health sciences","volume":"28","author":"Haraldstad","year":"2019","journal-title":"Qual. Life Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1345\/aph.17215","article-title":"Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy","volume":"33","author":"Markowitz","year":"1999","journal-title":"Ann. Pharmacother."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7130","article-title":"A systematic review of atypical antipsychotic drugs in schizophrenia","volume":"7","author":"Bagnall","year":"2003","journal-title":"Health Technol. Assess."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jad.2003.07.005","article-title":"Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid","volume":"81","author":"Namjoshi","year":"2004","journal-title":"J. Affect. Disord."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1440-1819.2004.01237.x","article-title":"Quality of life and its correlates in patients with bipolar disorder stabilized on lithium prophylaxis","volume":"58","author":"Chand","year":"2004","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Vittengl, J.R., Jarrett, R.B., Ro, E., and Clark, L.A. (2023). Associations of antidepressant medication consumption with changes in personality pathology and quality of life among community-dwelling adults. Int. J. Risk Saf. Med., preprint.","DOI":"10.3233\/JRS-230016"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/wps.20927","article-title":"Meeting the challenges of the new frontier of youth mental health care","volume":"21","author":"Malla","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/wps.20923","article-title":"Youth psychiatry: Time for a new sub-specialty within psy-chiatry","volume":"21","author":"Cannon","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/wps.20931","article-title":"Bridging between youth psychiatry and child and adolescent psychiatry","volume":"21","author":"Danese","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/wps.20797","article-title":"Mental health services on the roof of the world","volume":"21","author":"Xiang","year":"2022","journal-title":"World Psychiatry"}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/13\/11\/1577\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:21:00Z","timestamp":1760131260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/13\/11\/1577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":170,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["brainsci13111577"],"URL":"https:\/\/doi.org\/10.3390\/brainsci13111577","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]}}}